Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
If you check the number of shares sold per sale, only 3 out of the 1000+ trades so far were sells selling more than 4 digits of numbers of shares... It seems like it‘s just small investors (who are disappointed by the fact that the deal isn‘t amazon?).
It's understandable we are all getting impatient with this situation. We also want the share price to go up and get updates all the time. No need to turn against one another. If there‘s nothing to post about, don‘t post (note to self). Just be patient, ignore the noise from the usual scaremongers, as well as the swings. Perfectly normal that it doesn‘t follow a straight line. And let the PR people do their job.
"It is a major accomplishment to have generated Affimer reagents that can work in pairs as well as singly, as this opens up the potential for detecting the detached spike proteins as well as the intact virus particles, which means that we should have the best possible COVID-19 antigen test. "
It says it in the text really. One group binds to the spike proteins (1) while the other to the intact virus particles (2). Instead of having one option to detect, there are two. Maybe not a perfect analogy, but imaging you have a house with front entrance and a garage. If you have the key to the front entrance you can enter that way. If you have a garage key you can enter another way. If you have both you can enter both ways.
From the presentation
"A COVID-19 antigen test strip is expected to cost ~$2 to manufacture, sell to consumers for ~$30 and to large healthcare/corporate customers in bulk for $15 per test. Avacta has initiated discussions with distributors and OEM partners."
Hold and enjoy! I was thinking they‘d make it cheaper but hey, good for holders.
Strange drop this morning, the RNS was pretty positive to me. People need to learn how to read and ignore noise.
https://www.statnews.com/2020/04/29/nih-initiative-covid-19-testing/
"...an effort it says will result in the deployment of “millions of tests per week” by late summer or fall of this year."
Avacta is ahead of the game the way I read this, as their target has been set earlier. Possibly they would apply for this but (2 so far) collaborations and possible path to success already exist, so again ahead of others who may want to get a share of this money. This is also by any indication another proof that there won‘t be just one solution, nobody will have a monopoly. We need all kind of testS (antibody, antigen, PCR, MS..), as well as treatmentS and vaccineS. The more the merrier. Let‘s hope for everybody‘s sake this gets figured out soon. Avacta look to be in a great position regarding their CoV endeavours. Good luck all!
People keep asking about this. https://avacta.com/how-a-lateral-flow-rapid-test-works/ In this presentation (Avacta website from 15/04/2020, "How a Lateral Flow Rapid Test Works" in case the link gets blocked) at 2:53 it clearly says "suitable for test strips" and a green check mark as well as "Avacta and commercial partners have developed rapid point-of-care test strips for several applications" on the slide. Not sure if that removes any last doubt people have. Good luck all invested (and those not invested who will also hopefully benefit from this).
I don‘t think it is necessarily correct to say the VP visited Cytiva. It says "GE Healthcare" in the background of the video. It doesn‘t say "VP visiting GE Healthcare, now Cytiva". GE Healthcare still exists on its own right https://www.linkedin.com/company/gehealthcare/ (Linkedin of the GE Healthcare, in case the link gets deleted). Cytiva is formerly GE Healthcare "Life Sciences" subdivision. https://www.linkedin.com/company/cytiva/ (Linkedin of the Cytiva). Here https://en.wikipedia.org/wiki/GE_Healthcare (GE Healthcare wikipedia), it says
" - Life Sciences (LS), led by Emmanuel Ligner, headquartered in Little Chalfont, Buckinghamshire, UK.
- Produces technology for drug discovery, biopharmaceutical manufacturing, cellular technologies products for cell and gene therapies. Also researches, manufactures and markets pharmaceutical diagnostics used in medical imaging. "
On the Danaher Corporation wikipedia https://en.wikipedia.org/wiki/Danaher_Corporation it reads:
" In March 2020, Danaher acquired Cytiva, the life science business of General Electric, for $21.4 billion. The unit makes equipment for the research and manufacture of pharmaceuticals.[37]
[37]https://www.prnewswire.com/news-releases/danaher-completes-acquisition-of-the-biopharma-business-of-general-electric-life-sciences-business-will-be-called-cytiva-301032965.html "
It‘s important not to conflate everything. The Cytiva collaboration is huge, agreed. Hopefully more announced this week. Things are looking promising and, as all of us (even people unaware of AIM or Avacta), I am hoping for more positive news in terms of going back to normal.
Got in at ~0.14 after it being on my radar since the start of the year and averaged up to ~0.36 and holding until a possible takeover or at least end of year or early 2021. Good luck all. Ignore the noise, be curious, and meticulous.
While I do hope to US Gov endorses Avacta (Cytiva/Danaher are US companies so it would fit in with their buy American mantra), I wouldn‘t bank on it. There are more companies than we know around the world currently aiming to develop fast and reliable tests. If it turns out Avacta‘s isn‘t the one mentioned by Trump, I wouldn‘t lose faith in the share either (especially since many here holding for more than a month weren‘t even in it for the test). Several tests can and hopefully will succeed.
Who here has a netflix account? disney+? Who here is with EE? O2? Do people here go to Tesco? Waitrose? How about multiple? etc. Competition is healthy, and don‘t we all want to go back to normal?
Just out of curiosity, do RNS have to happen out of business hours?
Only been actively investing in biotech/AIM since the start of the year and I can only remember out of hours updates (other than monitoring extensions). And I don‘t normally pay too much attention to what happens during the day, or at least I don‘t act on it impulsively (n.b. anymore, learning curve with a few other companies).
I figure there will be RNS updates on new collaborations before announcing the outcome of their testing product (and pre-orders?), so possibly 2/3 in the next month. If positive, there shouldn't be much driving the average share price down again for a while as there would be constant and considerable revenue for months if not years, based on COVID-19 alone before news on the oncology products.
PS. I‘ve had my eye on this for a few months before the testing was on the table, got in luckily almost at the bottom (0.14) and have added more averaging up (0.24) seeing interesting it became in short term also. I wouldn‘t put a number on success to failure ratio on the testing. You‘ll always only end up putting your hopes too high into the direction you want it to go. Be realistic about it, bitterness and overoptimism will only lead to rash decisions and most likely to losing £. The people controlling the market know what they are doing and are taking advantage of this. It‘s important to see things in perspective. Like many here I like the odds, otherwise I wouldn‘t be in and holding. In clinical trials, new drugs have a incredibly low chance of success through all stages (which is in part why Pharma companies make drugs so expensive before they become generic, to fund all the failed attempts) but this is not a new drug per se. Holding this no matter what as it‘s an incredibly fascinating company with a few potential breakout products both in the short and longer term. Good luck all.